🔎 Trials Near Me

Home › Ovarian Cancer › NCT04294927

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Recruiting

TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.

Who can join

Ages 25 to 50 · Women

Full eligibility criteria
Inclusion Criteria:

* Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers.
* Age at inclusion;

  * BRCA1: 25-40 years
  * BRCA2: 25-45 years
  * RAD51C, RAD51D, BRIP1: 25-50 years
* Childbearing completed
* Presence of at least one fallopian tube
* Participants may have a personal history of non-ovarian malignancy
* Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution.

Exclusion Criteria:

* Postmenopausal status (natural menopause or due to treatment)
* Wish for second stage RRO within two years after RRS
* Legally incapable
* Prior bilateral salpingectomy
* A personal history of ovarian, fallopian tube or peritoneal cancer
* Current diagnosis or treatment for malignant disease

About the study

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

What is being tested

Sponsor: University Medical Center Nijmegen · Participants: 3,000 · Started: Mar 1, 2020

Contact the study team

Official record on ClinicalTrials.gov — NCT04294927

Locations in the U.S.

IllinoisUChicago Medicine, Chicago
MassachusettsDana Farber Cancer Institute, Boston
MinnesotaMayo Clinic, Rochester
MissouriWashington University Medical Center, St Louis
New YorkMemorial Sloan Kettering Cancer Center, New York
Mount Sinai Hospital, New York
North CarolinaDuke University Hospital, Durham
PennsylvaniaHospital of the University of Pennsylvania, Philadelphia
TexasHarris Health Lyndon B. Johnson Hospital, Houston
MD Anderson Cancer Centre, Houston
WashingtonUniversity of Washington, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.